Davide Campobasso1, Giampaolo Siena2, Paolo Chiodini3, Enrico Conti4, Francesco Franzoso5, Daniele Maruzzi6, Evangelista Martinelli7, Francesco Varvello8, Cosimo De Nunzio9, Riccardo Autorino10, Bhaskar Kumar Somani11, Giovanni Ferrari12, Luca Cindolo12,13. 1. Department of Urology, University Hospital of Parma/Azienda Ospedaliero-Universitaria di Parma, Parma, Italy. d.campobasso@virgilio.it. 2. Department of Urology, Careggi Hospital, University of Florence, "San Luca Nuovo", Florence, Italy. 3. Medical Statistics Unit, University of Campania "Luigi Vanvitelli", Naples, Italy. 4. Department of Urology, Levante Ligure Hospital, La Spezia, Italy. 5. Department of Urology, Desio Hospital, Desio, Italy. 6. Department of Urology, "S. Maria Degli Angeli" Hospital, Pordenone, Italy. 7. Department of Urology, "SS. Annunziata" Hospital, Taranto, Italy. 8. Department of Urology, "Michele e Pietro Ferrero" Hospital, Alba-Bra, Italy. 9. Department of Urology, "Sant'Andrea" Hospital, Sapienza University, Roma, Italy. 10. Division of Urology, Virginia Commonwealth University (VCU) Health, Richmond, VA, USA. 11. Department of Urology, University Hospital Southampton NHS Foundation Trust, Southampton, UK. 12. Department of Urology, "Hesperia Hospital", and CURE Group, Modena, Italy. 13. Department of Urology, "Villa Stuart" Private Hospital, Rome, Italy.
Abstract
BACKGROUND: The Rezum system is one of the latest minimally invasive surgical treatments for benign prostatic hyperplasia. METHODS: We retrospectively reviewed all patients who underwent the Rezum treatment in seven different Italian institutions. A successful urinary outcome was defined as: ≥50% improvement in the IPSS <7, improvement in peak flow ≥50% and/or more than 15 ml/s, ≥1-point improvement in the QoL questionnaire and in the absence of perioperative major complications (AUR, transfusion) or postoperative incontinence. A successful sexual outcome was defined as postoperative (latest follow up consultation) antegrade ejaculation or no variation in ejaculatory function and an increase, or stability or max 1 class reduction, in IIEF-5. RESULTS: 262 patients were enrolled with a follow-up period of 11 months (IQR 5-15). No early or late serious adverse events (Clavien III-IV) occurred. Early complications occurred in 39.3% of cases, with 4 cases of clot retention and one case of blood transfusion. Urge incontinence was reported by 6 patients (2.2%). A treatment failure requiring re-intervention occurred in 4 cases (1.5%). The preoperative antegrade ejaculation rate was 56.5%, and after the procedure it increased to 78.2%. The increase of ≥1-point in the QoL was achieved in 92.7% of the cases. Optimal urinary and sexual outcomes were achieved in 52.9% and 87.8%, respectively. CONCLUSIONS: In our series, water vapor intraprostatic injections seem to be an effective and safe procedure.
BACKGROUND: The Rezum system is one of the latest minimally invasive surgical treatments for benign prostatic hyperplasia. METHODS: We retrospectively reviewed all patients who underwent the Rezum treatment in seven different Italian institutions. A successful urinary outcome was defined as: ≥50% improvement in the IPSS <7, improvement in peak flow ≥50% and/or more than 15 ml/s, ≥1-point improvement in the QoL questionnaire and in the absence of perioperative major complications (AUR, transfusion) or postoperative incontinence. A successful sexual outcome was defined as postoperative (latest follow up consultation) antegrade ejaculation or no variation in ejaculatory function and an increase, or stability or max 1 class reduction, in IIEF-5. RESULTS: 262 patients were enrolled with a follow-up period of 11 months (IQR 5-15). No early or late serious adverse events (Clavien III-IV) occurred. Early complications occurred in 39.3% of cases, with 4 cases of clot retention and one case of blood transfusion. Urge incontinence was reported by 6 patients (2.2%). A treatment failure requiring re-intervention occurred in 4 cases (1.5%). The preoperative antegrade ejaculation rate was 56.5%, and after the procedure it increased to 78.2%. The increase of ≥1-point in the QoL was achieved in 92.7% of the cases. Optimal urinary and sexual outcomes were achieved in 52.9% and 87.8%, respectively. CONCLUSIONS: In our series, water vapor intraprostatic injections seem to be an effective and safe procedure.
Authors: Andrea Cocci; Alessia Celeste Bocchino; Gianmartin Cito; Antonello De Lisa; Giorgio Ivan Russo; Arturo Lo Giudice; Francesco Sessa; Lorenzo Viola; Luca Cindolo; Bhaskar K Somani; Giampaolo Siena Journal: Turk J Urol Date: 2021-11
Authors: Giampaolo Siena; L Cindolo; G Ferrari; D Maruzzi; G Fasolis; S V Condorelli; F Varvello; F Visalli; S Rabito; S Toso; S Caroassai; A Mari; L Viola; B K Somani; M Carini Journal: World J Urol Date: 2021-03-31 Impact factor: 4.226
Authors: Micheal F Darson; Erik E Alexander; Zvi J Schiffman; Michael Lewitton; Robert A Light; Mark A Sutton; Carlos Delgado-Rodriguez; Ricardo R Gonzalez Journal: Res Rep Urol Date: 2017-08-21